Developing a cost-effective method for producing proteins used in therapies.
Official title: A new platform for inexpensive and scalable recombinant protein and growth factor production to support cell culture applications in therapeutics.
Funded at Opera Bioscience, INC. · NIH-10699041 · Data updated 2026-11-12
This study is working on a new way to make important proteins for treatments like CAR-T cell therapy using a special bacteria, which could help make these therapies cheaper and easier for patients to get.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Opera Bioscience, INC. NIH-funded |
| Lab location | 1 site (Evanston, UNITED STATES) |
| Project start | September 20, 2024 |
| Project end | September 19, 2025 |
| Funding year | 2024 |
| Award (this year) | $275,765 |
| NIH project number | 1R43GM146560-01A1 |
| Project ID | NIH-10699041 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for benefiting from this research include patients requiring therapies that utilize recombinant proteins, such as those undergoing CAR-T cell treatments.
✕Less likely to help
Patients who do not require recombinant protein therapies or those with conditions not addressed by this research may not see any benefit.
What this research studies
This research focuses on creating a new platform that utilizes a bacterial system to produce growth factors and recombinant proteins more efficiently and at a lower cost. By leveraging the type III secretion system of Salmonella, the project aims to streamline the production process, which is crucial for developing therapies like CAR-T cell treatments. Patients could benefit from more affordable and accessible therapies as a result of this innovative approach to protein production.
Why it matters
Potential benefit: If successful, this research could significantly reduce the costs associated with producing therapeutic proteins, making advanced treatments more accessible to patients.
How similar studies have gone: Previous research has shown promise in using bacterial systems for protein production, indicating that this approach could lead to successful outcomes.
Where this research is happening
-
Opera Bioscience, INC.
Evanston, United States Active
Researchers
- Principal investigator: Liang, Julie Ming — Opera Bioscience, INC.
- Study coordinator: Liang, Julie Ming
Related research
Other NIH-funded projects on the same topics.
-
Developing a cost-effective method for producing therapeutic proteins.
This study is working on a new way to produce important proteins that help with treatments like CAR-T cell therapy, using a special bacteria to make the process faster and cheaper, so more people can benefit from these therapies.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.